BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30
• 31

• Press Releases

  Aurora to Participate in TD Cowen’s 9th Annual Future of the Consumer Conference

  May 27, 2025

   · 

  5 min read
• Press Releases

  VectorY Therapeutics Appoints Jessica Atkinson as Chief Business Officer

  May 27, 2025

   · 

  2 min read
• Press Releases

  US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection

  May 27, 2025

   · 

  19 min read
• Press Releases

  LENZ Therapeutics to Present at Upcoming Investor Conferences

  May 27, 2025

   · 

  1 min read
• Press Releases

  Avalyn Announces Upcoming Presentation on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the European Congress of Rheumatology 2025

  May 27, 2025

   · 

  1 min read
• Press Releases

  Nyra Medical Strengthens Executive Team with Strategic Appointments in Regulatory, Clinical, and Product Development Leadership

  May 27, 2025

   · 

  3 min read
• Press Releases

  ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

  May 27, 2025

   · 

  10 min read
• Press Releases

  AskBio Announces Publication of Complete Results of Phase 1b Trial of AB-1005 Gene Therapy in Participants with Parkinson’s Disease in Movement Disorders

  May 27, 2025

   · 

  11 min read
• Press Releases

  Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

  May 27, 2025

   · 

  5 min read
• Press Releases

  Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis

  May 27, 2025

   · 

  6 min read